Gregg Peterson, MA Bexson Biomedical

Gregg Peterson is CEO of Bexson Biomedical, a R&D stage pharmaceutical company focused on non-opioid therapies for pain management and mental health. He has over 20 years experience developing pharmaceutical, medical device, biologic and combination products, leading to commercial launch of over a dozen products globally. Gregg has held positions of increasing responsibility at both S&P500 companies and start-ups.  He has a successful history running R&D programs in US, EU and AsiaPac, from market analysis and ideation through Phase I-III clinical trials and to regulatory approval.  Gregg is a veteran of multiple pharma startup companies with successful exits including Evolus (IPO), TargeGen (sale to Sanofi-Aventis) and Somaxon (IPO).

In 2020 Bexson Biomedical signed an agreement with Stevanato Group to co-develop a wearable infusion device to for subcutaneous therapies.  The project's initial focus will be delivering Bexson's BB106 non-opioid therapy for acute pain management.